Guggenheim Capital LLC Cuts Stake in Amedisys, Inc. (NASDAQ:AMED)

Guggenheim Capital LLC lowered its position in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 11.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,063 shares of the health services provider’s stock after selling 1,359 shares during the quarter. Guggenheim Capital LLC’s holdings in Amedisys were worth $974,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Covestor Ltd grew its stake in shares of Amedisys by 88.9% during the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after purchasing an additional 152 shares during the period. Lazard Asset Management LLC acquired a new position in shares of Amedisys during the 1st quarter worth $68,000. Neo Ivy Capital Management acquired a new position in shares of Amedisys during the 2nd quarter worth $44,000. IFP Advisors Inc grew its stake in shares of Amedisys by 331.1% during the 3rd quarter. IFP Advisors Inc now owns 569 shares of the health services provider’s stock worth $47,000 after purchasing an additional 437 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in shares of Amedisys during the 1st quarter worth $262,000. Hedge funds and other institutional investors own 96.17% of the company’s stock.

Amedisys Stock Performance

NASDAQ AMED opened at $86.34 on Wednesday. Amedisys, Inc. has a one year low of $79.30 and a one year high of $179.91. The company’s 50 day moving average price is $90.30 and its 200 day moving average price is $95.71. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.09 and a current ratio of 1.09. The firm has a market capitalization of $2.81 billion, a price-to-earnings ratio of 23.72, a PEG ratio of 2.48 and a beta of 1.04.

Amedisys (NASDAQ:AMED – Get Rating) last posted its quarterly earnings results on Thursday, February 16th. The health services provider reported $1.16 EPS for the quarter, beating the consensus estimate of $1.03 by $0.13. Amedisys had a net margin of 5.34% and a return on equity of 15.44%. The firm had revenue of $562.10 million for the quarter, compared to analyst estimates of $560.46 million. During the same quarter last year, the firm posted $1.18 earnings per share. Amedisys’s revenue for the quarter was up .5% compared to the same quarter last year. On average, sell-side analysts predict that Amedisys, Inc. will post 4.27 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on AMED shares. Benchmark reissued a “buy” rating and issued a $120.00 price objective on shares of Amedisys in a research note on Monday, February 13th. Stephens reissued an “equal weight” rating and issued a $95.00 price objective on shares of Amedisys in a research note on Thursday, February 16th. Royal Bank of Canada lowered their price objective on shares of Amedisys from $114.00 to $111.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 21st. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Friday, February 17th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $115.00 price objective on shares of Amedisys in a research note on Monday, February 27th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $121.53.

About Amedisys

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.